Answers are grounded in this paper and cite their sources.
This overview highlights increased Clostridium difficile infections and the evolving management strategies that emerge from recent findings.
There is a surge of new interest in C. difficile infection (CDI) reflecting substantial increases in cases and fatalities. The new challenges by this now old pathogen have brought renewed interest in all facets of the disease. Particularly important are the role of fluoroquinolones as inducing agents, the new polymerase chain reaction test to detect toxigenic strains in stools, the important role of the NAP-1 strain, recent evidence favoring oral vancomycin over metronidazole in seriously ill patients, and new guidelines for management.
No takes yet. Share an insight, caveat, or question.
John G. Bartlett (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: